NCT03725436: ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+
Other Mutations: MYC
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only ER+ & HER2-negative patients are eligible for the dose expansion phase
Exclusions: Patients with TP53 mutation; Patients with symptomatic central nervous system (CNS) metastases by history, clinical signs or radiologic findings- see trial for details

Comments are closed.

Up ↑